Story perspectives

New Insights on NMDA Receptors Transform Depression Treatments

9/12/2025

Summary

Story summary

Recent studies highlight NMDA receptors, specifically GluN2A and GluN2D subunits, in depression treatment.
Research shows ketamine's rapid antidepressant effects may result from its influence on GABA interneurons in the medial prefrontal cortex.
A study suggests sevoflurane may act as an antidepressant by targeting specific NMDA receptors.
Findings emphasize parvalbumin interneurons' role in mood regulation, linking their dysfunction to depression and schizophrenia.
Ongoing research seeks to develop new antidepressants targeting glutamatergic neurotransmission pathways.

1 of 1

Story summary

Recent studies highlight NMDA receptors, specifically GluN2A and GluN2D subunits, in depression treatment.
Research shows ketamine's rapid antidepressant effects may result from its influence on GABA interneurons in the medial prefrontal cortex.
A study suggests sevoflurane may act as an antidepressant by targeting specific NMDA receptors.
Findings emphasize parvalbumin interneurons' role in mood regulation, linking their dysfunction to depression and schizophrenia.
Ongoing research seeks to develop new antidepressants targeting glutamatergic neurotransmission pathways.